AstraZeneca’s Soriot Says Mega-Mergers Can Work, But Is Hush Hush On Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca did not address rumors it has become an acquisition target of Pfizer during its first quarter conference call. CEO Soriot did say that some mega-mergers can work, but such deals have to be evaluated on a case-by-case basis.